Biogen Idec and Alnylam to Collaborate on RNAi Therapeutics for PML | GenomeWeb
NEW YORK (GenomeWeb News) - Biogen Idec and Alnylam will jointly develop RNAi therapeutics to treat progressive multifocal leukoencephalopathy, the companies said today.
Biogen Idec will finance all research and development activities and Alnylam will receive an upfront payment of $5 million.
Alnylam will also receive more than $51 million in milestone payments, royalties, and utilization fees if the collaboration successfully develops any therapeutic products.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.